Alexza Pharmaceuticals: New Opportunity
Edison | Nov 03, 2015 07:13
Regaining US Adasuve rights, new opportunity?
Alexza (O:ALXA) and Teva (N:TEVA) have reached an agreement whereby Alexza will reacquire the US commercial rights for Adasuve, with a projected target completion date of 1 January 2016. US sales since the March 2014 launch have been tepid (Teva-derived product revenue to Alexza was under $3m) and recent developments at Teva (ie Actavis (N:AGN) acquisition) may have deprioritized Adasuve’s position within the firm. While Teva’s Adasuve relinquishment may reflect a reduced long-term sales outlook, the process may actually help facilitate Alexza’s ongoing strategic review. An outright sale or royalty agreement for Alexza’s entire interest in Adasuve may be more straightforward once US rights are regained.
In September 2015, Alexza retained an investment bank to examine strategic options (including asset sales or a business combination) to enhance shareholder value and lower the cost of capital for advancing pipeline projects including AZ-007 (Staccato zaleplon). Alexza also secured a $5m loan from EU partner Ferrer to maintain sufficient liquidity to complete the review and secure a deal.
To Read the Entire Report Please Click on the pdf File Below
Get The App
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.